HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MYASTHENIA GRAVIS AND GENERALIZED MYASTHENIA GRAVIS IN FRANCE: RELIEF, A CLAIMS-BASED STUDY
Author(s)
Jean-Baptiste Noury, Dr1, Didier Theis2, Erika Guyot, PhD3, Maeva Nolin, MaSc3, Manon Belhassen, MPH, PhD3, Ingrid Rodriguez, Pharm D4, Julia Meijer, PhD4, Laurène Gautier, MaSc5, JULIEN DUPIN, MASc5, Thierry Gendre, Dr6.
1Centre de Référence Des Maladies Neuromusculaires AOC, INSERM, LBAI, UMR1227, CHRU de Brest, Brest, France, 2CHU de Lille, Lille, France, 3EPIMENTIS, Lyon, France, 4Medical Affairs, J&J Innovative Medicine, Issy-les-Moulineaux, France, 5Medical Affairs, J&J Innovative Medicine, Issy-Les-Moulineaux, France, 6APHP, CHU Henry Mondor, Créteil, France.
1Centre de Référence Des Maladies Neuromusculaires AOC, INSERM, LBAI, UMR1227, CHRU de Brest, Brest, France, 2CHU de Lille, Lille, France, 3EPIMENTIS, Lyon, France, 4Medical Affairs, J&J Innovative Medicine, Issy-les-Moulineaux, France, 5Medical Affairs, J&J Innovative Medicine, Issy-Les-Moulineaux, France, 6APHP, CHU Henry Mondor, Créteil, France.
OBJECTIVES: Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder with heterogeneous healthcare needs. Generalized MG (gMG) represents a more severe form with a generalized muscle weakness and may be associated with higher healthcare resources utilization (HCRU) and costs. This study aimed to describe HCRU and direct costs among patients with MG and gMG in France.
METHODS: RELIEF is a retrospective observational study using the French National Healthcare Data System (SNDS). Incident MG and gMG adults were identified in 2022 using claims‑based algorithms combining ICD‑10 codes from hospitalization records, long‑term disease status and MG‑specific treatment dispensing. HCRU and reimbursed direct medical costs were estimated over the 12 months following MG and gMG diagnosis and summarized using medians with [IQR] and means with SD.
RESULTS: The study included 1,197 patients with MG and 859 patients with gMG. Total costs were high in gMG and MG (median: €17,037 [7,590-36,449] vs. €11,574 [3,672-28,721]; mean: €29,648 (43,336) vs. €24,218 (42,433)). Hospitalization occurred in 75.2% of patients in both groups, with median costs of €3,941 [0-13,483] in gMG and €3,796 [0-12,397] in MG. Admissions involving ICU during medical hospital stays were observed in 27.8% of gMG and 26.1% of MG patients. In gMG, short‑term immunotherapies (intravenous immunoglobulins or plasma exchange) were administered to 71.0% of patients and emerged as the largest cost component with a median cost of €5,054 [0-10,108], exceeding median hospitalization costs. Similar HCRU patterns between MG and gMG may reflect overlap due to rapid progression and claims-based identification.
CONCLUSIONS: This nationwide real‑world study demonstrates that while hospitalizations dominate MG and gMG healthcare costs, the primary cost drivers differ. During the first year following gMG diagnosis, short‑term immunotherapies contribute more to overall expenditures. These findings highlight the burden of gMG and the need for new strategies to meet its unmet needs.
METHODS: RELIEF is a retrospective observational study using the French National Healthcare Data System (SNDS). Incident MG and gMG adults were identified in 2022 using claims‑based algorithms combining ICD‑10 codes from hospitalization records, long‑term disease status and MG‑specific treatment dispensing. HCRU and reimbursed direct medical costs were estimated over the 12 months following MG and gMG diagnosis and summarized using medians with [IQR] and means with SD.
RESULTS: The study included 1,197 patients with MG and 859 patients with gMG. Total costs were high in gMG and MG (median: €17,037 [7,590-36,449] vs. €11,574 [3,672-28,721]; mean: €29,648 (43,336) vs. €24,218 (42,433)). Hospitalization occurred in 75.2% of patients in both groups, with median costs of €3,941 [0-13,483] in gMG and €3,796 [0-12,397] in MG. Admissions involving ICU during medical hospital stays were observed in 27.8% of gMG and 26.1% of MG patients. In gMG, short‑term immunotherapies (intravenous immunoglobulins or plasma exchange) were administered to 71.0% of patients and emerged as the largest cost component with a median cost of €5,054 [0-10,108], exceeding median hospitalization costs. Similar HCRU patterns between MG and gMG may reflect overlap due to rapid progression and claims-based identification.
CONCLUSIONS: This nationwide real‑world study demonstrates that while hospitalizations dominate MG and gMG healthcare costs, the primary cost drivers differ. During the first year following gMG diagnosis, short‑term immunotherapies contribute more to overall expenditures. These findings highlight the burden of gMG and the need for new strategies to meet its unmet needs.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE564
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders, Rare & Orphan Diseases